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Table 1. Outcome Following IV versus IB Xeno-transplantion
Group: IV IB XRT Control Untreated Control P (comparing IV vs. IB)
Median Survival (days) 22 >42 >42 >42 <0.0001
% Surviving at 6 weeks 24% (7/29) 83% (25/30) 100% (10/10) 100% (5/5) <0.0001
Median Hgb at 3 weeks (g/dL) 10.5 (n511) 10.8 (n520) 11.2 (n55) 11.3 (n55) 0.23
Median WBC at 3 weeks (K/uL) 1.46 2.65 1.02 1.16 0.025
Median Plt at 3 weeks (K/uL) 871 1080 930 1443 0.23
Median Human leukocytes (cells/ul) at 3 weeks 67 36 NA NA 0.38
Median % weight change at 3 weeks –13.6% (n516) –6.1% (n530) –5.1% (n510) 0.3% (n55) 0.03
Median Hgb at 6 weeks (g/dL) 9.1 (n57) 10 (n519) 13.1 (n55) 12.7 (n55) 0.12
Median WBC at 6 weeks (K/uL) 0.4 6.78 2.92 2.42 <0.0001
Median Plt at 6 weeks (K/uL) 84 729 986 1270 0.009
Median Human leukocytes (cells/ul) at 6 weeks 178 1005 NA NA 0.0003
Median % weight change at 6 weeks –11.1% (n57) –8.7% (n524) –2.8% (n510) 2.5% (n55) 0.7
Oral Presentations S167strain is an exceptional model for studying xeno-engraftment of hu-
man lympho-hematopoietic cells. We compared survival following
tail-vein (IV) vs. intrafemoral (IB) xeno-transplantation of T-cell
replete G-CSF mobilized human peripheral blood stem cells (G-
PBMNC) into NSG mice.
Methods:NSGmice underwent irradiation with 250 cGy followed 6
hours later by transplantation of 5x106 G-PBMNCs given either IV
(200 mL) or IB (5 mL) under isoflurane anesthesia. Paired mice (IV
vs. IB)were transplantedwith cells froma singledonor.Miceuntreated
or irradiated with 250 cGy that did not receive human cells served as
controls. Following transplantation, mice were weighed weekly and
were phlebotomized tomeasure complete blood counts and to quanti-
tate the % of engrafting human cells by FACS over the 6 week study
period. Necropsy was performed on mice from each group.
Results: Engraftment of human leukocytes was detectable in both
the IB and IV transplant recipients.Median survival was significantly
shorter in IV transplanted mice (22 days) compared to IB trans-
planted mice, where median survival was not reached at 6 weeks (p
\ 0.0001). IV recipients manifested more severe xeno-GVHD
symptoms than IB transplanted mice, losing significantly more
weight and becoming pancytopenic with bone marrows showing se-
vere hypo-cellularity which likely occurred as the consequence of
a graft-versus-murine hematopoiesis effect. In contrast, recipients
of IB transplanted cells did not develop pancytopenia despite having
significantly higher levels of engrafted human cells.
Conclusions: IB xeno-transplantation of humanG-PBMNCs results
in higher degrees of human leukocyte engraftment than IV transplan-
tation while simultaneously protecting the host fromGVHD. In con-
trast, recipients of IV transplantsweremore likely to loseweight and to
develop pancytopenia and marrow aplasia which significantly short-
ened survival compared to IB transplanted mice. These data suggest
the IB route of transplantation should be further studied as a method
to overcome GVHD associated with HLA disparity.42
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We have previously identified five biomarker proteins that have
diagnostic and prognostic value for acute graft-versus-host disease
(GVHD) (Blood 113:273-278, Sci Transl Med 2:50-57). To deter-
mine whether biomarkers can predict GVHD before the appearance
of clinical symptoms, we measured the three most informative bio-
markers (IL2Ra, TNFR1, elafin) by sequential ELISA in patient
samples prospectively obtained prior to conditioning (pre-HCT),
on day17, and day114 after hematopoietic cell transplant (HCT)
from 513 unrelated (URD) HCT patients. We randomly divided
the patients into training (N 5 342) and validation (N 5 171) data
sets that were balanced for (i) full intensity conditioning, (ii) earlyonset of grade II-IV GVHD (\ day121), and (iii) HCT performed
after 2005. We used the training data set to simulate biomarker
values for a hypothetical 50,000 patients using the following assump-
tions: (1) the incidence of GVHD by day 100 is 55%; (2) the median
day of GVHD onset after full intensity URD HCT is day 21, with
10% developing GVHD prior to day17, and 3% after day156.
We used logistic regression to assign each of the 50,000 patients to
low risk and high risk of developing grade II-IV GVHD based
upon the biomarker levels pre-HCT and at day17. We measured
all three biomarkers again in samples taken at day114 in all patients
whowere categorized as low risk and who did not developGVHDby
day114. We determined with another logistic regression model
which low risk patients had now moved to the high risk category.
In the training data set, the combination of these two analyses cor-
rectly predicted the continued absence of grade II-IV GVHD (i.e.
specificity) in 77% (95% CI: 71%-83%) and correctly predicted
the eventual development of GVHD (i.e. sensitivity) in 50% (95%
CI: 42%-58%) of patients. In the validation data set, these tests
gave a specificity of 75% (95% CI: 67%-83%) and a sensitivity of
57% (95% CI: 44%-69%), (Table 1, first row).
Table 1. Sensitivity and Specificity Corresponding to Various
Values of Predicted Probability at Days +7 and +14 Applied to
Validation Data Set
Combined Specificity Combined Sensitivity Correct Prediction of
for both cutpoints for both cutpoints GVHD by Day 5675% 57% 65%
74% 48% 60%
73% 49% 60%
71% 58% 64%
70% 57% 63%The median time between a high risk determination and onset of
grade II-IV GVHD was 14 days. These cutpoints also led to the
greatest correct prediction of GVHD facilitating the design of a trial
to test preemptive treatment of GVHD using these panels. In con-
clusion, measurement of a three-biomarker panel pre-HCT, at
day17, and day114 predicts grade II-IVGVHDwith good specific-
ity (75%) and fair sensitivity (57%).43
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Wehave previously shown that blocking the L-mevalonate pathway
by statins reduces acute graft-versus-host disease (GvHD) in the mu-
rine bone marrow transplanation (BMT) model (Zeiser R et al. Blood
Table 1. Associations between decreasing mean levels of cal-
cineurin inhibitors and outcomes in patients who had non-
myeloablative hematopoietic cell transplantation. Mean levels
of cyclosporine and tacrolimus within the first month after
transplant were 340 ng/mL and 12 ng/mL, respectively. Hazard
ratios (HR) are shown according to 10% decrements relative to
mean levels of respective calcineurin inhibitor.
Datum
Cyclosporine (n5280) Tacrolimus (n5127)
HR (95% CI) P HR (95% CI) P
Acute GVHD 2-4 1.18 (1.10-1.26) <0.0001 1.04 (0.93-1.15) 0.51
Acute GVHD 3-4 1.13 (0.99-1.28) 0.06 1.22 (0.94-1.58) 0.13
Chronic GVHD 0.99 (0.90-1.08) 0.81 0.90 (0.83-1.00) 0.04
Relapse 1.07 (0.93-1.22) 0.35 0.97 (0.88-1.08) 0.62
NRM 1.31 (1.12-1.54) 0.0009 1.21 (0.91-1.62) 0.19
OM 1.10 (1.01-1.19) 0.02 1.07 (0.97-1.18) 0.19
GVHD – graft versus host disease, NRM – non relapse mortality, OM –
overall mortality.
S168 Oral Presentations2007). The impact of statins on alloreactivity was reproducible when
human cells where studied in vitro and recent retrospective clinical
studies demonstrated that statin treatmentwas associatedwith reduced
acute GvHD and chronic GvHD in patients with cyclosporine-based
immunosuppression. Downstreammetabolites of the pathway are far-
nesylpyrophosphates, geranylgeranylpyrophosphates and squalene.
Currently, the relevance of the different metabolites for the immuno-
modulatory effect of statins on GvHD and immune reconstitution is
unclear. Therefore, we applied Farnesyl-transferase inhibitor (FTI)
and Geranylgeranyl-transferase inhibitor (GGTI) or Zaragocic acid
tomurineBMTrecipients.Treatment ofwithFTIandGGTI reduced
GvHD severity and prolonged survival significantly (vehicle versus
FTI p 5 0.0001, vehicle versus GGTI p 5 0.0007) in 2 different
BMTmodels. Improved survival was paralleled by lower serum levels
of TNF-a (vehicle vs FTI p\0.01) and MCP-1 (vehicle vs FTI p\
0.01 or vsGGTI p\0.05). Mechanistically we observed that geranyl-
geranylation and farnesylationwere required for cytoskeletal organiza-
tion and migration of antigen presenting cells (APC) in vitro.
Compatible with this observation, bioluminescence based tracking
demonstrated reduced recruitment of APC towards lymphoid organs
in vivo. FTI and GGTI treatment resulted in reduced ERK1/2 signal-
ing inT cells and affected their alloantigen driven expansion. Interfer-
ing with donor alloreactive T cell expansion in vivo led to increased
thymic cellularity, higher thymocyte counts and a more diverse TCR
repertoire as determined by PCR based spectratyping. These effects
were not seen when squalene production was blocked. FTI and
GGTI did not compromise donor peripheral T cell function since
B-cell lymphoma rejection and MCMV immunity remained intact.In
summary we observed an immunomodulatory effect of FTI/GGTI
onGvHDwhich enhanced numerically intact, diverse immune recon-
stitution with functional anti-tumor and anti-MCMV effects. These
studies are the first to delineate the relative contributions of Farne-
syl-transferase andGeranylgeranyl-transferase to the protective effects
against GvHD observed under statin treatment.44
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To determine whether calcineurin inhibitor (CNI) blood concen-
trations within the first month after allogeneic hematopoietic cell
transplantation (HCT) correlated with the onset of graft-versus-
host disease (GVHD) and other outcomes, we retrospectively ana-
lyzed data from 1181 patients with hematologic malignancies who
had HCT from HLA-matched related (n 5 634) or unrelated (n 5
547) donors at a single institution between 2001 and 2009. Aftermye-
loablative HCT (n 5 774), lower CNI blood levels were not associ-
ated with higher risks for acute or chronic GVHD, even though
higher cumulative doses of glucocorticoids during the first 100 days
were required for treatment of acuteGVHDamongpatients given ta-
crolimus prophylaxis (p5 0.007). In contrast, after nonmyeloablative
HCT (n5 407), lower cyclosporine blood levels were associatedwith
increased risks of grade 2-4 and 3-4 acute GVHD (hazard ratio [HR]
5 1.18, 95% confidence interval [CI]1.10-1.26, p\0.0001; and HR
5 1.13, 95%CI 0.99-1.28, p5 0.06, respectively), non relapse mor-
tality (NRM) (HR5 1.31 95%CI 1.12-1.54, p5 0.0009) and overall
mortality (OM) (HR51.10, 95%CI1.01-1.19, p50.02).In addition,
each 10% increment inmean cumulative blood levels of cyclosporine
above 340 ng/ml, was associated with a 4.3 mg/kg reduction of the
cumulative glucocorticoids dose during the first 100 days after
HCT (p\0.0001). Cyclosporine blood levels within the first month
after HCT were not associated with risks of chronic GVHD and re-
current malignancy after nonmyeloablative HCT. Among patients
given tacrolimus after nonmyeloablative HCT, a potential similar
trend of CNI-associated GVHD-protection was observed. HigherCNI blood levels were not associated with renal toxicity. We con-
clude that higher CSP blood levels during the first month after non-
myeloablative HCT confer protection against acute GVHD that
translates into reduced risks of NRM and OM without affecting
the risks of chronic GVHD or recurrent malignancy.45
HIGH FREQUENCY OF ALLOANTIGEN-SPECIFIC T-Regs IN HUMAN
BLOOD ALLOW RAPID EX VIVO EXPANSION FOR ADOPTIVE THERAPY
Veerapathran, A.1,2, Pidala, J.1,3, Beato, F.1,2, Yu, X.-Z.1,3,
Anasetti, C.1,2,3 1Moffitt Cancer Center, Tampa, FL; 2Moffitt Cancer
Center; 3Moffitt Cancer Center
Adoptive transfer of regulatoryT (Treg) cells prevents allograft re-
jection and graft-vs-host disease (GVHD) in experimental animals.
Since Treg function is driven by recognition of specific antigen, we
have established a technique for selective expansion of human allo-
specific Treg ex vivo. In this study, we show that a high frequency
ofCD41CD251CD127-Tregs inhumanblooddo recognize specific
alloantigen and can be expanded to numbers adequate for adoptive
immunotherapy trials. Treg were isolated from normal human blood
and stimulated by HLA-mismatched APC’s, in the presence of IL-2
and IL-15 to amplify the proliferative responses, and sirolimus to sup-
press non-Tregs. The precursor frequency of antigen specific Tregs
was 1.02 % (95% Confidence Interval; 0.65 - 1.59) and non-Tregs
1.56% (95% C.I; 0.94 - 2.55), as calculated by Limiting Dilution
Analysis. Tregs showed a duplication time of approximately 24 hours
in the presence alloantigen, cytokines and sirolimus, and were ex-
panded in vitro by 793 (95%C.I; 480 - 1107) fold in a 12 day period.
Purified Tregs were labeled with CFSE before culture with alloanti-
gen, cytokines and sirolimus. After 12 days in culture, flow-sorted
CFSE-lowTregs exhibited 90% suppression against CD25-negative
CD4 T cell responses up to ratios of 1:20; in contrast, CFSE-high
Tregs were not suppressive. CFSE-low Tregs did not suppress the
proliferation of non-Tregs against third party alloantigen, demon-
strating that their suppressionwas antigen specific. Ex vivo expanded,
antigen specific Tregs maintained high expression of Foxp3, lym-
phoid homing receptorCD62L and chemokine receptorCCR7, pre-
dicting that they will remain functional and able to migrate to
lymphoid tissues in vivo. The expanded Tregs produced IL-10,
TGF-b and expressed cytoplasmic CTLA-4 to significantly higher
accounts compared to non-Tregs, suggesting these molecules may
be involved in the mechanism of regulation. Our data provide a plat-
form for the selective expansion of Tregs against major histocompat-
ibility antigens. This magnitude of expansion predicts the feasibility
of conducting translational clinical trials for prevention of GVHD.
